Emulgel
$ 51,00 – $ 323,00Price range: $ 51,00 through $ 323,00
Endep
$ 22,00 – $ 398,00Price range: $ 22,00 through $ 398,00
Enclomisign
$ 85,00 – $ 189,00Price range: $ 85,00 through $ 189,00
Enclomisign is an advanced therapeutic option specifically developed to treat secondary hypogonadism in men. This selective estrogen receptor modulator effectively stimulates the natural production of luteinizing hormone and follicle-stimulating hormone within the body. By enhancing these natural processes, the medication helps restore optimal testosterone levels while maintaining the body’s internal hormonal balance. Unlike many standard treatments, Enclomisign supports endogenous sperm production, making it a specialized solution for male reproductive health. This medication provides a reliable way to address hormonal deficiencies and improve overall male wellness.
Active substance: Enclomiphene
SKU:
Enclomisign
Categories: Men's Health, Woman's Health
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM
Each dosage option has its own packaging choices.
Description
Enclomisign belongs to a group of pharmaceutical compounds known as selective estrogen receptor modulators. The active agent selectively antagonizes estrogen receptors at the hypothalamic-pituitary level to influence downstream gonadotropin secretion.
In the United States, this medication is dispensed in accordance with applicable federal and state regulations under the direct supervision of a licensed healthcare provider.
| Attribute | Specification |
|---|---|
| Active ingredient | Enclomiphene citrate |
| Therapeutic class | Selective Estrogen Receptor Modulator (SERM) |
| Dosage form | Oral tablet / capsule |
| Route of administration | Oral |
| Primary purpose | Modulation of endogenous gonadotropin secretion |
| Prescription status | Dispensed per state and federal prescription regulations |
How the drug works
The mechanism of action of Enclomisign relies on its properties as a selective antagonist at nuclear estrogen receptors in the hypothalamus and anterior pituitary gland. Under normal physiological conditions, circulating estrogen exerts a negative feedback signal on the central nervous system, reducing the secretion of Gonadotropin-Releasing Hormone (GnRH) and subsequent gonadotropins.
By competitively binding to these specific central receptors, Enclomisign prevents endogenous estrogen from initiating negative feedback. This blockade stimulates the hypothalamic release of GnRH, which in turn prompts the anterior pituitary to synthesize and secrete Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). In males, the elevation of systemic LH acts directly upon Leydig cells within the testes to stimulate endogenous testosterone biosynthesis.
Main uses
Enclomisign is evaluated for conditions involving functional suppression of the hypothalamic-pituitary-gonadal axis. Its primary clinical interest lies in restoring natural gonadotropin production and supporting testicular hormone synthesis without suppressing spermatogenesis.
In American medical practice, the administration of enclomiphene for secondary male hypogonadism or functional androgen deficiency is considered an off-label use. Off-label prescribing implies that while the compound is selected based on clinical evidence and pharmacological rationale, the specific indication has not received formal FDA approval on a standardized package insert label. Therapeutic initiation requires comprehensive diagnostic testing, including baseline serum testosterone, LH, FSH, prolactin, and liver function panels.
First days of treatment
Upon commencing treatment with Enclomisign, physiological changes occur primarily at the hormonal level rather than producing instantaneous physical sensations. The dynamic shift in pituitary hormone secretion begins within days of starting daily administration, although clinical laboratory confirmation typically occurs several weeks into therapy.
Patients should not rely on subjective markers during the initial days of administration. Objective response is evaluated by scheduled follow-up blood tests ordered by a physician to measure total serum testosterone, free testosterone, estradiol, and hematocrit levels.
Dosing schedule
The administration schedule for Enclomisign must be strictly defined by a prescribing physician based on initial baseline endocrine laboratory values. The oral dosage is taken once daily, with or without food, around the same time each day to maintain steady therapeutic systemic concentration.
Dosage adjustments are determined solely through follow-up serum assays. Patients must not alter the daily regimen, double doses, or stop treatment abruptly without direct instruction from their healthcare provider. Regular compliance with laboratory work schedules in a state-certified facility (such as in Texas or California) is essential to monitor endocrine response and ensure safety.
What happens in the body
Following oral administration, Enclomisign is absorbed through the gastrointestinal tract. Peak plasma concentration of the trans-isomer (enclomiphene) is reached within relatively short timeframes, followed by extensive distribution into systemic tissues.
The compound demonstrates high plasma protein binding. Hepatic transformation serves as the primary route of metabolism, mediated predominantly by cytochrome P450 enzyme systems. Elimination occurs primarily through biliary and fecal pathways, with renal excretion playing a minor role. The elimination half-life of enclomiphene is relatively short compared to cis-isomers (zuclomiphene), resulting in reduced systemic accumulation upon chronic administration.
Adverse reactions
Treatment with Enclomisign may produce adverse effects of varying intensity. The clinical safety profile includes common mild reactions as well as uncommon reactions that necessitate medical oversight.
- Central Nervous System: Headache, dizziness, fatigue, and mild mood alterations.
- Gastrointestinal: Nausea, abdominal discomfort, and diarrhea.
- Vascular/Dermatologic: Hot flashes, mild flushing, and transient sweating.
- Hematologic/Endocrine: Elevated hematocrit levels, potential increase in serum estradiol due to peripheral aromatization of increased testosterone, and minor testicular discomfort.
- Ocular Disturbances: Blurred vision, visual scotoma, photopsia (flashing lights), or altered visual accommodation.
If visual symptoms occur, the medication must be discontinued immediately, and an urgent ophthalmic evaluation should be performed.
Compatibility with other medicines
The concurrent use of Enclomisign with other pharmacological agents requires careful clinical review to prevent adverse drug interactions. Combining this agent with exogenous androgenic therapy (such as testosterone gels, injections, or implants) or anabolic steroids counteracts its intended mechanism, as exogenous androgens suppress pituitary LH and FSH release.
Concomitant administration with strong inhibitors or inducers of hepatic CYP450 enzymes may alter the metabolic clearance and systemic exposure of Enclomisign. Patients taking medications metabolized by hepatic pathways or drugs affecting sex hormone-binding globulin (SHBG) must inform their prescriber prior to initiating treatment.
Food and alcohol interactions
Oral absorption of Enclomisign is not significantly altered by standard nutritional intake. The medication may be taken independently of meal times.
Ethanol consumption should be limited during therapy. Chronic or high-volume alcohol consumption directly depresses hypothalamic and testicular function, which counteracts the therapeutic effect of gonadotropin stimulation. Additionally, both alcohol and SERM metabolism place metabolic demands on hepatic clearance pathways.
If you skip a dose
If a single daily dose of Enclomisign is missed, the patient should take the missed tablet as soon as it is remembered on that day. However, if the time is close to the next scheduled dose, the missed dose should be skipped entirely, resuming the regular daily timing.
Under no circumstances should two doses be ingested simultaneously to make up for a missed tablet. Compensatory doubling increases systemic drug levels and elevates the risk of adverse reactions.
Important precautions
Enclomisign is contraindicated in patients with known hypersensitivity to the active substance, pre-existing liver disease, severe hepatic impairment, or active thromboembolic disorders. The safety and effectiveness of this compound in pediatric populations have not been established.
In female patients, pregnancy must be definitively ruled out prior to administration due to potential teratogenic risks. Male patients undergoing therapy should undergo periodic baseline and follow-up screening for prostate health (including Prostate-Specific Antigen testing) and hematocrit monitoring to evaluate secondary erythrocytosis.
Storage and expiration
Enclomisign should be stored at controlled room temperature between 20°C and 25°C (68°F to 77°F), with temporary excursions permitted between 15°C and 30°C (59°F and 86°F) in accordance with standard USP storage guidelines.
Keep the container tightly closed, away from excessive moisture, heat, and direct sunlight. Store the product safely out of reach of children and domestic animals. Discard any unused or expired medication following local municipal hazardous waste guidelines or pharmacy take-back programs.
Common questions
How does Enclomisign differ from exogenous testosterone replacement therapy?
Exogenous testosterone therapy introduces synthetic or bioidentical androgen directly into the bloodstream, which signals the pituitary gland to shutdown endogenous LH and FSH production, leading to testicular atrophy and suppressed spermatogenesis. Enclomisign acts centrally to stimulate the body’s own pituitary gland to release LH and FSH, thereby promoting natural testicular production of testosterone and maintaining testicular volume and germ cell development.
What specific visual changes require immediate discontinuation of Enclomisign?
Any manifestation of blurred vision, reduced visual acuity, spotty vision (scotoma), flashes of light, or sensitivity to light requires immediate cessation of the drug. These ocular symptoms suggest central SERM activity affecting visual pathways and mandate an urgent examination by an ophthalmologist.
Why are periodic blood tests required during treatment with Enclomisign?
Routine laboratory monitoring is critical to assess both efficacy and safety. Blood tests track serum total testosterone, free testosterone, LH, FSH, and estradiol levels to determine if the dosage requires titration. Additionally, monitoring red blood cell parameters (hematocrit and hemoglobin) is necessary to ensure the patient does not develop erythrocytosis, a known risk of elevated androgen activity.
Can Enclomisign be taken alongside over-the-counter dietary supplements?
Patients should disclose all dietary supplements, vitamins, and herbal products to their healthcare provider before beginning therapy. High-dose hormonal precursors or supplements claiming to boost testosterone independently may complicate clinical evaluation, interact with liver clearance pathways, or interfere with pituitary feedback loops.
What should a patient do if mild gastrointestinal upset occurs during daily administration?
If mild nausea or stomach discomfort occurs after taking the dose, taking the tablet with a light meal or snack can often mitigate gastrointestinal irritation. If nausea persists, worsens, or is accompanied by abdominal pain or yellowing of the skin or eyes, the patient must contact their prescribing physician immediately for clinical evaluation.
In accordance with FDA requirements.
This text is for informational purposes only and does not constitute individual medical advice.
Additional information
| Dosage |
50 mg |
|---|---|
| Package |
30 pills ,60 pills ,90 pills |
| Ενεργός Ουσία |
Related products
Anaconda
$ 87,00 – $ 225,00Price range: $ 87,00 through $ 225,00
Active substance: Sildenafil Citrate
More Details
This product has multiple variants. The options may be chosen on the product page
Betahistine
$ 41,00 – $ 311,00Price range: $ 41,00 through $ 311,00
Active substance: Betahistine
More Details
This product has multiple variants. The options may be chosen on the product page
Bottled Levitra
$ 158,00 – $ 347,00Price range: $ 158,00 through $ 347,00
Active substance: Vardenafil
More Details
This product has multiple variants. The options may be chosen on the product page
Cardura
$ 40,00 – $ 313,00Price range: $ 40,00 through $ 313,00
Active substance: Doxazosin
More Details
This product has multiple variants. The options may be chosen on the product page
Extra Super P-Force
$ 72,00 – $ 199,00Price range: $ 72,00 through $ 199,00
Active substance: Dapoxetine, Sildenafil Citrate
More Details
This product has multiple variants. The options may be chosen on the product page
Ferrous
$ 60,00 – $ 487,00Price range: $ 60,00 through $ 487,00
Active substance: Ferrous sulfate
More Details
This product has multiple variants. The options may be chosen on the product page
Finalo
$ 26,00 – $ 52,00Price range: $ 26,00 through $ 52,00
Active substance: Finasteride
More Details
This product has multiple variants. The options may be chosen on the product page
Lotrisone
$ 41,00 – $ 254,00Price range: $ 41,00 through $ 254,00
Active substance: betamethasone, Clotrimazole
More Details
This product has multiple variants. The options may be chosen on the product page
